0001437749-26-010878
SEC filingcbdMD, Inc. shareholders approved the 2025 Equity Compensation Plan, elected seven directors, ratified the auditor, and authorized a reverse stock split and share issuances at the 2026 Annual Meeting on March 30, 2026.
At the 2026 Annual Meeting, cbdMD shareholders approved all seven proposals with quorum of 54.6% of 10,495,561 outstanding shares. The 2025 Equity Compensation Plan approval enables equity incentives for employees, officers, directors, and consultants, starting with 891,316 shares and an evergreen provision adding up to 2% of outstanding shares annually (max 300,000), supporting talent retention amid the company's capital raise activities. This immediately triggered issuance of 445,000 restricted shares to CEO/CFO T. Ronan Kennedy under his November 2025 employment agreement, aligning executive incentives with shareholder interests. Director elections saw strong support for Kennedy and Porter (over 2.8M For votes), with moderate withholdings. Auditor ratification passed decisively despite 1.6M abstentions. The reverse stock split authorization gives the board flexibility to adjust share structure for compliance or attractiveness. Crucially, approvals for Series B/C preferred conversions and ELOC with C/M Capital Master Fund, LP remove exchange caps, facilitating institutional funding but risking dilution beyond 20% of outstanding shares, a key consideration for investors monitoring capital structure and equity value.